Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility
ECONOMY & POLICY

Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility

Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.

The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.

In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.

Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.

Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.

News source: The Hindu


Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.News source: The Hindu

Related Stories

Gold Stories

Next Story
Resources

NCC Founder and Padma Shri Awardee AVS Raju Passes Away at 89

Dr Alluri Venkata Satyanarayana Raju, founder and Chairman Emeritus of NCC Limited and a Padma Shri awardee, passed away in Hyderabad on 13 October 2026. He was 89.Born on 18 April 1937 in Antarvedipalem village in Andhra Pradesh's erstwhile East Godavari district, Raju began his entrepreneurial journey in 1956. He established Nagarjuna Construction Company (NCC) Limited in 1978, which subsequently emerged as one of India's leading construction and infrastructure companies.Under his leadership, NCC became a public limited company in 1990 and expanded into one of India's prominent listed constr..

Next Story
Infrastructure Transport

Embraer to Acquire 51 Per Cent Stake in Mahindra Aerospace Arm

Brazilian aerospace major Embraer will acquire a 51 per cent equity stake in Novavayu Aerospace, a step-down subsidiary of Mahindra and Mahindra, under an Investment Agreement notified by the automobile company in an exchange filing. The transaction will give Embraer control of the aerospace business. Following completion of the acquisition, Novavayu Aerospace will cease to be a wholly owned subsidiary and become an associate of Mahindra Defence Systems, which is a step-down wholly owned subsidiary of Mahindra and Mahindra. The agreement is expected to be completed on or before December 1. Mah..

Next Story
Infrastructure Urban

RBI Opens Special Dollar Window for Three State-Run OMCs

The Reserve Bank of India (RBI) has opened a special facility to meet the entire daily US dollar requirements of three public sector oil marketing companies (OMCs), in a move aimed at easing pressure on the Indian rupee. The facility will take effect on October 12, 2026, and remain available until further notice. Indian Oil Corporation, Hindustan Petroleum Corporation and Bharat Petroleum Corporation are eligible to use the arrangement. Under the facility, the RBI will sell US dollars to the three companies through designated banks, allowing them to meet their oil-import payments without sourc..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code